Conclusions: Overall response rate to nivo in patients with HIV-related lymphomas was 100%, one-year OS -83,3%. Toxicity and immune-related adverse effects were not registered. Preliminary data provide that nivo is effective and safety treatment option for r/r HIV-related lymphoma. and Study 325 were 24% (4/17) and 21% (6/28), respectively (9 partial responses; 1 complete response; see Table) . T-VEC-related adverse events (AEs) in CPI-experienced pts in Study 324/Study 325, respectively, were: Grade 3 AEs 18%/21%; serious AEs 18%/11%; AEs leading to permanent T-VEC discontinuation 12%/4%. Conclusions: Although this retrospective analysis has limitations, the ORR with T-VEC in pts previously treated with a CPI was consistent with the ORR observed with T-VEC in the phase 3 OPTiM trial. Types and incidence of AEs were consistent with the known safety profile of T-VEC. These data suggest that T-VEC demonstrates measurable activity for melanoma pts who have received a prior CPI and have an injectable metastasis. Clinical trial identification: NCT02366195; NCT02014441. Legal entity responsible for the study: Amgen Inc. Funding: Amgen Inc. Background: Between 2010 and 2015, pivotal trials with strict enrolment criteria led to the approval of several new immunotherapies for metastatic melanoma (MM). We sought to determine the impact of these treatments in the "real-world" of a populationbased study. IQVIA OD is a syndicated database collecting longitudinal, anonymized, patient-level oncology data through a quarterly physician panel survey. The UK panel characteristics were: 94% public, 65% university, 12% Scotland/Northern Ireland -6% Wales -82% England. The response rate ranged 13-72% among circa 225 physicians per quarterly pulse. Data on patient/disease characteristics, Tx, and biomarkers were extracted and analysed. Results: In total, data from 738 stage IIIb/IV NSCLC patients receiving 1L cancer Tx were analysed. At questionnaire completion, 57% of patients were male and 68% were aged >60 years. Most patients had cancers with non-squamous histology (79%); fewer had squamous (20%) and other (1%). ECOG performance status was assessed as 0 in 14% and 1 in 76% of patients, and metastases were mostly found in the lung (49%), bone and liver (34% each), lymph nodes local (36%) and distant (25%). COPD was the most common comorbidity (28%); 40% of patients reported none. 49% were former smokers and 22% current smokers. Chemotherapy and targeted therapies were the most frequent 1L Tx received by 301 (41%) and 219 (30%) patients, respectively. 30% of patients (n ¼ 218) received IO Tx in 1L; pembrolizumab was the most common IO therapy (n ¼ 216, 29%). PD-L1 testing was performed among 76% of the latest quarter patients (n ¼ 195/255); 106 (54%) were positive (PD-L1þ; 50%), 82 (42%) negative (PD-L1-; <50%) and 7 awaiting results. Most PD-L1þ patients received pembrolizumab in 1L (86%), whereas PD-L1-patients were mostly treated with chemotherapy (73%) and one third received targeted therapies. Conclusions: In the current UK treatment landscape for stage IIIb/IV NSCLC, only 30% of patients were treated with IO Tx in 1L. A high proportion of 1L patients is still treated with traditional chemotherapy. Editorial acknowledgement: Editorial assitance was provided by Eleonora Morais from IQVIA. Legal entity responsible for the study: Outcome Sciences LLC (an IQVIA company).
IQVIA OD is a syndicated database collecting longitudinal, anonymized, patient-level oncology data through a quarterly physician panel survey. The UK panel characteristics were: 94% public, 65% university, 12% Scotland/Northern Ireland -6% Wales -82% England. The response rate ranged 13-72% among circa 225 physicians per quarterly pulse. Data on patient/disease characteristics, Tx, and biomarkers were extracted and analysed. Results: In total, data from 738 stage IIIb/IV NSCLC patients receiving 1L cancer Tx were analysed. At questionnaire completion, 57% of patients were male and 68% were aged >60 years. Most patients had cancers with non-squamous histology (79%); fewer had squamous (20%) and other (1%). ECOG performance status was assessed as 0 in 14% and 1 in 76% of patients, and metastases were mostly found in the lung (49%), bone and liver (34% each), lymph nodes local (36%) and distant (25%). COPD was the most common comorbidity (28%); 40% of patients reported none. 49% were former smokers and 22% current smokers. Chemotherapy and targeted therapies were the most frequent 1L Tx received by 301 (41%) and 219 (30%) patients, respectively. 30% of patients (n ¼ 218) received IO Tx in 1L; pembrolizumab was the most common IO therapy (n ¼ 216, 29%). PD-L1 testing was performed among 76% of the latest quarter patients (n ¼ 195/255); 106 (54%) were positive (PD-L1þ; 50%), 82 (42%) negative (PD-L1-; <50%) and 7 awaiting results. Most PD-L1þ patients received pembrolizumab in 1L (86%), whereas PD-L1-patients were mostly treated with chemotherapy (73%) and one third received targeted therapies. Conclusions: In the current UK treatment landscape for stage IIIb/IV NSCLC, only 30% of patients were treated with IO Tx in 1L. A high proportion of 1L patients is still treated with traditional chemotherapy. Editorial acknowledgement: Editorial assitance was provided by Eleonora Morais from IQVIA. Legal entity responsible for the study: Outcome Sciences LLC (an IQVIA company). The aim of this study was to establish the most effective treatment using a network meta-analysis (NMA) based on all the available randomized controlled trials. Methods: We conducted an independent review for the RCTs evaluating ICIs in frontline advanced NSCLC. A meta-analysis was performed on the primary outcome of OS using the inverse variance heterogeneity method. The Cochrane Q test for heterogeneity was computed and the I 2 coefficient was used to quantify the extent of betweenstudy heterogeneity. A threshold for statistical significance of 0.10 was used for the Cochrane Q test and heterogeneity was considered to be substantial if I 2 > 60%. Since the heterogeneity was found to be both statistically significant and substantial for the primary outcome, it was judged that a pooled analysis would not be representative of the true treatment effect hence a NMA was computed instead. The NMA was computed by utilizing a frequentist approach with generalized pairwise modeling. Results: Network estimates of effects on OS showed the superiority of pembroþplati-num doublet compared to all the other regimens: pembro (HR ¼ 1.39, 95%CI 1.02-1.89); atezoþplatinum doublet (HR ¼ 1.72, 95%CI 1.31-2.26); ipiþplatinum doublet (HR ¼ 1.62, 95%CI 1.28-2.04), nivo (HR ¼ 1.82, 95%CI 1.35-2.47) and platinum doublet (HR ¼ 1.79, 95%CI 1.49-2.14). The superiority of pembroþplatinum doublet was also consistent on PFS except when compared to pembro (HR ¼ 1.78, 95%CI 0.72-4.42) and ORR except when compared to ipiþplatinum doublet (HR ¼ 0.33, 95%CI 0.07-1.44), where the comparisons did not reach the threshold of statistical significance. Conclusions: Our results support the superiority of pembrolizumab þ platinum doublet in the frontline treatment of NSCLC. However, the main limitation of this study is that, due to the limited available data, differences in patient and tumor (pathology and PDL-1 status) characteristics could not be accounted for. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
64P Post-progression evaluation of patients treated with nivolumab for advanced non-small cell lung cancer: A prospective cohort analysis E. Quaquarini
